Filtered By:
Specialty: Urology & Nephrology
Management: European Medicines Agency (EMA)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Androgens and cardiovascular risk: A series of case report in the French and Canadian pharmacovigilance databases.
CONCLUSION: Our study shows a very low report of cardiovascular effects under testosterone, all doubtful. Pending further studies, it seems reasonable to consider the cardiovascular risk of patients who are candidates for hormone therapy for age-related androgen deficiency.
LEVEL OF EVIDENCE: 3.
PMID: 29650456 [PubMed - as supplied by publisher]
Source: Progres en Urologie - April 15, 2018 Category: Urology & Nephrology Tags: Prog Urol Source Type: research
